Senseonics (NYSE:SENS) said today that Blue Cross Blue Shield of Massachusetts and Idaho now provide coverage for the implantable Eversense continuous glucose monitor.
The company’s Eversense device includes a fluorescence-based sensor, a mobile app and a transmitter. Senseonics’ touts its system as being the first with a long-term, implantable CGM sensor, as well as the first to have a smart transmitter.
Get the full story at our sister site, Drug Delivery Business News.